Donghoon Yoon
Associate Professor
faculty
Internal Med, College of Medicine
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Donghoon Yoon's research investigates molecular mechanisms underlying disease, with a focus on cancer and blood disorders. He has explored the role of specific genes and signaling pathways in diseases such as lymphoma and multiple myeloma. His work includes developing and validating animal models to better understand disease progression and test potential therapeutic strategies. Recent publications have examined novel therapeutic targets in lymphoma, the role of specific molecules in cancer cell apoptosis, and advancements in drug delivery systems using microneedles.
Yoon has a scholarly record of 144 publications, with an h-index of 18 and over 1,200 citations. He collaborates extensively with colleagues at the University of Arkansas for Medical Sciences, including Syed Hassan Mehdi, Ying-Zhi Xu, Samantha Kendrick, and Vijay Patel, with whom he shares numerous co-authored publications. His recent work also touches on the fabrication of solid microneedles for drug delivery and the cellular mechanisms of skin pigmentation.
Metrics
- h-index: 18
- Publications: 149
- Citations: 1,254
Selected Publications
-
Multimodal microneedle-based electrochemical sensors for continuous monitoring of the tumor microenvironment (2026)
-
Abstract 2246: GLUT3 inhibition reduces metastatic potential of triple-negative breast cancer cells by modulating cell mechanics via the TEAD-VASP-Actin axis. (2026)
-
Microneedle-Mediated Adaptive Phototherapy (MAP) Wound Patch with Microlens (2026)
-
The role of 7-dehydrocholesterol in inducing ER stress and apoptosis of head and neck squamous cell carcinoma (2025)
-
Self-Assembly of Microstructured Protein Coatings with Programmable Functionality for Fluorescent Biosensors (2024)
-
Development of New Diffuse Large B Cell Lymphoma Mouse Models (2024)
-
Advancing Drug Delivery with Pocket Microneedle Achieving Dual-Drug Synchronization (2024)
-
Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma (2023)
-
The Synthetic Collagen-Binding Peptide NIPEP-OSS Delays Mouse Myeloma Progression (2023)
-
Abstract 3828: Herbal extracts from lycii radicis corex and achyranthes japonica prevent multiple myeloma progression (2023)
-
Experimental Validation of Diffraction Lithography for Fabrication of Solid Microneedles (2022)
-
Abstract 1655: Development of humanized diffuse large B-cell lymphoma mouse models (2022)
-
Development of Humanized Diffuse Large B-Cell Lymphoma Mouse Models (2021)
Grants & Funding
- Study of Sigma Anti-Bonding Calcium (SAC) Role(s) in Multiple Myeloma and Cutaneous Wound Healing Calcium & Bone Health Institute Principal Investigator
- In Situ Imaging of Collagen Degradation Activity in Multiple Myeloma and Fibrosis Murine Models - Resubmission NIH/Office of the Director - Pass Through: University of Utah Principal Investigator
- Study of Sigma Anti-Bonding Calcium (SAC) Role(s) in Multiple Myeloma and Erythropoietin-Induced Osteoporosis Calcium & Bone Health Institute Principal Investigator
- Scientific and methodological advancement in liquid biopsies to further the development of lung cancer-based precision medicine U.S. Food and Drug Administration - Pass Through: Arkansas Research Alliance Co-Investigator
- Center for Musculoskeletal Disease Research (CMDR) NIH/Nat. Inst. of General Medical Sciences Select
Collaboration Network
Top Collaborators
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Animal Models of Multiple Myeloma Bone Disease
- An Improved Animal Model of Multiple Myeloma Bone Disease
- The role of 7-dehydrocholesterol in inducing ER stress and apoptosis of head and neck squamous cell carcinoma
- Development of New Diffuse Large B Cell Lymphoma Mouse Models
Showing 5 of 44 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Development of New Diffuse Large B Cell Lymphoma Mouse Models
- Development of Humanized Diffuse Large B-Cell Lymphoma Mouse Models
- Abstract 1655: Development of humanized diffuse large B-cell lymphoma mouse models
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 40 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Development of Humanized Diffuse Large B-Cell Lymphoma Mouse Models
- Abstract 1655: Development of humanized diffuse large B-cell lymphoma mouse models
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 39 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Development of Humanized Diffuse Large B-Cell Lymphoma Mouse Models
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 38 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Figure S6 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S9 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Table S12 from Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
Showing 5 of 37 shared publications
Similar Researchers
Based on overlapping research topics